|
|
|
23.06.25 - 09:45
|
Research: BOCOMI Ratings, TPs on Pharmas (Table) (AAStocks)
|
|
|
Stocks | Ratings | Target Prices AstraZeneca (AZN.US) | Buy | USD93.3 BEIGENE (06160.HK) | Buy | HKD208.8 HANSOH PHARMA (03692.HK) | Buy | HKD33 INNOVENT BIO (01801.HK) | Buy | HKD84 SINO BIOPHARM (01177.HK) | Buy | HKD5.9 SKB BIO-B (06990.HK) | Buy | HKD400 Legend Biotech (LEGN.US) | Buy | USD65 WUXI XDC (02268.HK) | Buy | HKD5......
|
|
|
04.06.25 - 22:33
|
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer (Business Wire)
|
|
|
MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch.
Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs.
In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herring...
|
|
|
03.06.25 - 16:48
|
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more....
|
|
|
22.05.25 - 23:18
|
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT (GlobeNewswire EN)
|
|
|
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology Association's (EHA) Congress. Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors, specifically lung and gastric cancers respectively, will also be featured in poster presentations at ASCO....
|
|
|
|
|
|
|
|
|
|
|
|
|
13.03.25 - 03:15
|
Research: BOCI Drops GENSCRIPT BIO TP to $21, Keeps Rating at Buy (AAStocks)
|
|
|
GENSCRIPT BIO (01548.HK)'s 2024 revenue amounted to US$594 million, with a net profit of US$2.9 billion, mainly driven by a US$3.2 billion one-time gain from the spin-off of Legend Biotech (LEGN.US), BOCI released a research report saying. Moreover, the core business reported a net loss of US$174 million, reflecting continue......
|
|
|
12.03.25 - 07:46
|
GenScript Biotech Corporation Reports FY 2024 Results (PR Newswire)
|
|
|
Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J., March 12, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and......
|
|
|
|
|
|
|
|
|
|
|
|
|
19.12.24 - 14:03
|
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT....
|
|
|
|
|
10.12.24 - 01:36
|
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire EN)
|
|
|
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual disease (MRD)-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD, compared to standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).1 MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma.1 These results reinforce the clinical value of CARVYKTI® as early as second line and support the recent achievement of overall survival (OS) benefit versus standard therapies1. The MRD negativity findings ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
